新型口服抗凝药防治急性静脉血栓栓塞症的研究进展

Progress on Novel Oral Anticoagulant in the Prevention and Treatment of Acute Venous Thromboembolism

急性静脉血栓栓塞症(AVTE)发病率较高,是临床常见的三大致死性血管疾病之一。抗凝治疗是防治AVTE的重要措施,传统抗凝药物包括肠外抗凝药物(如普通肝素及低分子肝素等)和维生素K拮抗剂,但其临床应用受限。近年来,新型口服抗凝药(NOACs)防治AVTE的有效性和安全性成为临床研究热点之一。本文对NOACs在AVTE治疗中的作用、NOACs的分类及其临床推荐方案、特殊情况下NOACs的应用、NOACs的实验室定性和定量分析、逆转NOACs相关性出血药物方面的最新研究进展进行综述。

Acute venous thromboembolism（ AVTE） is one of top three Fatal vascular diseases on clinic,with high morbidity. Anticoagulant therapy is one of important measures in preventing and treating venous thromboembolism. In recent years,effectiveness and safety of new oral anticoagulants（ NOACs） in the prevention and treatment of AVTE has been one of hot clinical topics. This paper mainly reviewed the latest research progress on treatment outcome, classification, clinical recommendations,application in particular cases, laboratory qualitative and quantitative analysis, related bleeding reversal drugs of NOACs.